Salgado J P, Khoramnia R, Maier M M, Lohmann C P, Winkler von Mohrenfels C
Augenklinik und Poliklinik, Universität Würzburg, Josef-Schneider-Strasse 11, Würzburg, Germany.
Ophthalmologe. 2011 Jun;108(6):561-4. doi: 10.1007/s00347-010-2327-0.
A patient undergoing combined therapy of chronic hepatitis C with pegylated interferon-α-2a (PEG-IFN-α-2a) and ribavirin suddenly developed severe loss of visual acuity. A central vein occlusion with macular edema was found and intravitreal injections of bevacizumab were initiated. Retinal occlusion is a known complication of therapy with pegylated interferon-α-2a and ribavirin. An interdisciplinary assessment of patients treated for a chronic hepatitis C as well as an early anti-VEGF administration can be helpful in the therapy of this complication of chronic hepatitis C.
一名接受聚乙二醇化干扰素-α-2a（PEG-IFN-α-2a）和利巴韦林联合治疗慢性丙型肝炎的患者突然出现严重视力丧失。发现中央静脉阻塞伴黄斑水肿，并开始玻璃体内注射贝伐单抗。视网膜阻塞是聚乙二醇化干扰素-α-2a和利巴韦林治疗的已知并发症。对接受慢性丙型肝炎治疗的患者进行多学科评估以及早期给予抗血管内皮生长因子（VEGF）治疗，可能有助于治疗慢性丙型肝炎的这一并发症。
